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Abstract
BACKGROUND: Iodine-131 (131I) is a well-established method
for the treatment of hyperthyroidism. Following such therapy,
patients may experience symptoms relating to early or delayed
side effects that can be prevented or minimized if necessary
measures are taken. We have noticed an unusual side effect of
131I therapy in the form of a skin eruption (iododerma) and aimed
at assessing the frequency and severity of this side effect.
MATERIAL AND METHODS: Retrospective review of 141 pa-
tients treated with 131I between January 1994 to December 2000
(86 F, 55 M; mean age 41.35 – 11.02 years) was performed.
The dose of 131I ranged from 250500 MBq. Post therapy clini-
cal and biochemical evaluation of thyroid function was done at
6 weeks, 3, 6, and 9 months then annually.
RESULTS: Of the 141 treated patients, 3 patients (2.1%) pre-
sented with iododerma 46 weeks after 131I therapy administra-
tion. Lesions were observed at both ankles & lower legs in all 3
cases. All lesions disappeared within 6 months with no residual
effect. No other skin lesions were seen thereafter during the
follow-up period.
CONCLUSION: Iododerma is a rare complication of 131I therapy
that has not been reported before. It appears within 46 weeks
after therapy and is a self-limiting condition.
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Introduction
Hyperthyroidism is a common endocrine disorder caused by
a multitude of conditions, the most common of which are Graves
disease, toxic multinodular goitre and autonomously functioning
thyroid nodule(s). The classic methods of treatment of hyperthy-
roidism i.e. antithyroid drugs, 131I and surgery, are effective but
have their individual advantages and disadvantages. The most
significant of the latter is the development of hypothyroidism, which
can take place after any of the above treatment modality with vari-
able duration, frequency and severity.
Treatment with 131I was introduced in 1942 [1] and was re-
served for patients over the age of 40 years or those unfit for sur-
gery or suffer of side effects of antithyroid medications, due to
fear of radiation-induced carcinogenesis or teratogenesis. Since
then various studies have shown that its use is not associated
with increased risk of carcinogenesis or teratogenesis [2, 3] and
confirmed its efficacy and safety compared to antithyroid medi-
cations and surgery [4]. The ease of administration and low cost
of 131I combine to make it an attractive method of treatment for the
majority of hyperthyroid patients worldwide. It is however not free
from side effects that are relatively less severe than other treat-
ment modalities and include hypothyroidism and rarely radiation
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thyroiditis, gastritis and sialadenitis. The development of exacer-
bation of hyperthyroidism and hypersensitivity to iodine are con-
sidered extremely rare.
We have noticed the development of a bilateral skin eruption
in the ankles and feet of one of our patients following therapy with
131I. There was no history of a previous dermatological disorders
nor a clinical or laboratory test to confirm other aetiology. The
purpose of this study was to review the case notes of all patients
treated with 131I between 1994 and 2000 to assess the frequency
and severity of this complication.
Material and methods
We studied the case notes of 141 patients with hyperthyroid-
ism who received 131I therapy and maintained regular follow-up in
the Center for Nuclear Medicine & Ultrasound, Khulna, Bangladesh
between January 1994 to December 2000. The mean age of the
patients was 41.35 – 11.02 years (range 2167 years) and the
female/male ratio was 1.56:1. Of these, 120 (85.1%) patients had
diffuse toxic goitre (Graves disease), 14 (9.9%) had toxic multi-
nodular goitre and 7 (5%) had autonomously functioning thyroid
nodules (toxic adenoma).
Diagnosis was done based on clinical manifestations and bio-
chemical criteria including elevated triiodthyronine (T3), thyroxine
(T4) and suppressed thyroid stimulating hormone (TSH). Thyroid
scintigraphy with 99mTc- pertechnetate was done in all patients to
assess the size and nodularity of the gland.
Elderly patients and all those with cardiac disease and severe
hyperthyroidism were pretreated with a short course of antithyroid
drugs in full dosages until they were clinically and biochemically
euthyroid. Medications were stopped 3 days before 131I treatment,
restarted 3 days later, and continued for 1 to 2 months depending
on the patients symptoms.
131I was not administered to female patients who were pregnant
or wishing to become so very soon after therapy. The likely conse-
quences of the treatment were fully explained to the patients and/or
relatives and partners. Full consent was obtained and precautions
aiming at radiation protection of the public were discussed.
The dose of 131I given to the patients was empirical with single
dose ranged from 250-500 MBq. Follow-up was done at 6 weeks,
3 months, 6 months, 9 months and then annually. Clinical and
biochemical evaluation of thyroid function was done in follow-up
visit. If the first dose was found to be ineffective in controlling dis-
ease activity, then a second dose was considered after proper
clinical and biochemical evaluation. The amount of 131I given in
the second dose was either the same or 50% more than the first
dose. During follow-up, patients were classified as cured if the
functional status was either euthyroid or hypothyroid within 1 year
without further treatment of hyperthyroidism by drugs or 131I.
Results
A single dose of 131I was given to 119 (84.4%) patients, and
a second dose was required in 22 (15.6%) patients. Of the 141 pa-
tients treated, 11 had severe hyperthyroidism and/or cardiac di-
sease necessitating treatment with antithyroid medications for
more than four weeks before treatment. These medications were
stopped 3 days before, restarted 3 days after 131I treatment, and
continued for 1 to 2 months. None of those patients developed any
skin manifestation relating to the use of antithyroid medication.
In our study, all patients were followedup for at least one
year following 131I treatment. One hundred and twenty five patients
(88.7%) were diagnosed as cured within one year. Hypothyroidism
at one year after 131I therapy was observed in 12 (8.5%) patients.
Three patients (2 males and 1 female), comprising 2.1% of all
treated cases, presented with skin lesions at 46 weeks after 131I
administration. The lesions were diagnosed as iododerma and
were observed on ankles and lower legs bilaterally in all cases,
with multiple inflamed follicular pustules and bullous formations
that become ulcerated and crusted (Figure 1).
No such lesions were seen in any other patient who received
131I therapy from the same source. The amount of sodium iodide
component of the dose was less than 4.2 mg in all patients. All
three patients had Graves disease. The female patient was pre-
treated with antithyroid medication for 2 weeks prior to 131I treat-
ment due to severe hyperthyroidism, while the two male patients
did not receive any antithyroid medication. The biochemical sta-
tus of the thyroid and the administered dose of I-131 of these
three patients are shown in Table 1. All skin lesions disappeared
within 6 months with no residual effect (Figure 2).
Discussion
131I therapy for hyperthyroidism has been well established for more
than 60 years. In contrast to surgery and antithyroid drugs, 131I is
a simple, inexpensive and effective mode of therapy. It is however
not free from side effects that are well documented and can be pre-
vented or minimized if appropriate measures are taken. Hypersensi-
tivity to iodine is extremely uncommon in association with 131I therapy
since the quantity of sodium iodide is infinitely small, usually in the
order of few micrograms. It is therefore a common practice to pre-
scribe 131I therapy to patients known to be hypersensitive to iodine.
Hypersensitivity to iodine is an idiosyncratic reaction that is
not dose-dependent [5, 6] and may cause a wide variety of skin
Figure 1. Photograph of lower limbs of patient number 1 showing iodo-
derma involving both ankles and hind feet.
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eruptions referred to as iododerma. The most common type is an
acneiform eruption with inflammatory follicular pustules. In mild
cases pruritis and urticaria may be manifested but vegetative or
fungating lesions may also occur [7]. Bullous lesions are also
common with ulceration and crustation. Iododerma may occur in
the face, neck, extremities and trunk.
In our study, iododerma of the ankles & lower legs occurred in
three (2.1%) patients within 46 weeks of treatment despite the
fact that they received less than 4.2 mg sodium iodide from 131I
therapy. The lesions were self-limiting and disappeared within
6 months with no residual effect.
Other possible causes of the rash have been excluded, as the
patients had no previous history of a dermatological or autoim-
mune disorders. It could not have been caused by idiosyncrasy
Table 1. Thyroid hormone levels & administered dose of I-131 in-patient with iododerma
No. Sex Age Dose [MBq] T3 [nmol/L] T4 [nmol/L] TSH [mIU/L]
1 M 47 296 4.56 284.05 0.24
2 M 42 370 4.78 293.06 0.12
3 F 40  296 7.71 > 300 Undetectable
to carbimazole in our female patient due to the difference in type
of eruption and time of onset. The rash that is associated with
carbimazole appears within 36 weeks of starting therapy [8], and
is commonly maculo-papular in type, accompanied by systemic
signs such as fever [9]. This is in contradiction to our case in
which the rash appeared 8 weeks after starting carbimazole the-
rapy in the form of multiple inflamed follicular pustules and bullous
formations followed by ulcerated and crustation.
Conclusion
This is the first report of three cases of iododerma of the an-
kles and feet developing within 46 weeks following 131I therapy
for hyperthyroidism. This early/intermediate side effect was seen
in around 2% of our treated patients. It is a self-limiting condition
that disappears completely within 6 months without any specific
treatment.  Patient may need to be notified about the possibilities
of developing this skin lesion along with other early side effect
before administering 131I therapy.
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Figure 2. Photograph of same patient as in figure 1 showing disappear-
ance of lesions within 6 months. The difference in skin colour of forefeet
and hind feet is due to wearing a sandal.
